15 research outputs found
Cancer epidemiology in Central and South Eastern European countries
Aim To collect cancer epidemiology data in South Eastern
European countries as a basis for potential comparison of
their performance in cancer care.
Methods The South Eastern European Research Oncology
Group (SEEROG) collected and analyzed epidemiological
data on incidence and mortality that reflect cancer management
in 8 countries – Croatia, Czech Republic, Hungary,
Romania, Poland, Slovakia, and Serbia and Montenegro
in the last 20-40 years.
Results The most common cancer type in men in all countries
was lung cancer, followed by colorectal and prostate
cancer, with the exception of the Czech Republic, where
prostate cancer and colorectal cancer were more common.
The most frequent cancer in women was breast cancer
followed by colorectal cancer, with the exceptions of
Romania and Central Serbia where cervical cancer was the
second most common. Cancer mortality data from the last
20-40 years revealed two different patterns in men. In Romania
and in Serbia and Montenegro, there was a trend
toward an increase, while in the other countries mortality
was declining, after increasing for a number of years. In
women, a steady decline was observed over many years
in the Czech Republic, Hungary, and Slovakia, while in the
other countries it remained unchanged.
Conclusions There are striking variations in the risk of different
cancers by geographic area. Most of the international
variation is due to exposure to known or suspected
risk factors which provides a clear challenge to prevention.
There are some differences in incidence and mortality that
cannot be explained by exposure to known risk factors or
treatment availabilities
Incidental Use of Beta-Blockers Is Associated with Outcome of Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Based Therapy: A Single-Institution Retrospective Analysis of 514 Patients
Background: Beta-adrenergic signalling plays an important role in several cancer-related processes, including angiogenesis. The impact of beta-blocker use on prognosis of cancer patients treated with antiangiogenic agents is unclear. The aim of this study was to evaluate the association between the incidental use of beta-blockers and the outcomes of patients with metastatic colorectal cancer (mCRC) treated with bevacizumab-based therapy. Methods: Clinical data from 514 mCRC patients treated with bevacizumab between 2005 and 2019 were analysed retrospectively. The association of progression-free survival (PFS) and overall survival (OS) with the incidental use of beta-blockers and other common antihypertensive drugs was assessed. Results: The median PFS and OS for patients using beta-blockers was 11.40 (95% confidence interval (CI) 10.10–13.61) months and 26.8 (95% CI 22.2–32.2) months compared with 8.30 (95% CI 7.80–9.57) and 21.0 (95% CI 17.8–23.8) months for patients not using beta-blockers (p = 0.006 and p = 0.009, respectively). In the Cox multivariate analysis, the use of beta-blockers was a significant factor predicting both PFS (hazard ratio (HR) = 0.763 (95% CI 0.606–0.960), p = 0.021) and OS (HR = 0.730 (95% CI 0.560–0.951), p = 0.020). Conclusions: The results of the present retrospective study suggest that there is a significant association between the use of beta-blockers and favourable outcomes of mCRC patients treated with bevacizumab-based therapy
Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients
Background: The Memorial Sloan–Kettering Cancer Center (MSKCC) prognostic model has been widely used for the prediction of the outcome of metastatic renal cell carcinoma (mRCC) patients treated with systemic therapies, however, data from large studies are limited. This study aimed at the evaluation of the impact of the MSKCC score on the outcomes in mRCC patients treated with first-line sunitinib, with a focus on the intermediate-risk group. Methods: Clinical data from 2390 mRCC patients were analysed retrospectively. Progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) were analysed according to the MSKCC risk score. Results: ORR, median PFS, and OS for patients with one risk factor were 26.7%, 10.1, and 28.2 months versus 18.7%, 6.2, and 16.2 months, respectively, for those with two risk factors (ORR: p = 0.001, PFS: p < 0.001, OS: p < 0.001). ORR, median PFS, and OS were 33.0%, 17.0, and 44.7 months versus 24.1%, 9.0, and 24.1 months versus 13.4%, 4.5, and 9.5 months in the favourable-, intermediate-, and poor-risk groups, respectively (ORR: p < 0.001, PFS: p < 0.001, OS: p < 0.001). Conclusions: The results of the present retrospective study demonstrate the suitability of the MSKCC model in mRCC patients treated with first-line sunitinib and suggest different outcomes between patients with one or two risk factors
Healthcare-resource utilization associated with radiation to bone across eight European countries: Results from a retrospective study
Background: Bone metastases and lytic lesions due to multiple myeloma are common in advanced cancer and can lead to debilitating complications (skeletal-related events [SREs]), including requirement for radiation to bone. Despite the high frequency of radiation to bone in patients with metastatic bone disease, our knowledge of associated healthcare resource utilization (HRU) is limited.
Methods: This retrospective study estimated HRU following radiation to bone in Austria, the Czech Republic, Finland, Greece, Poland, Portugal, Sweden and Switzerland. Eligible patients were ≥ 20 years old, had bone metastases secondary to breast, lung or prostate cancer, or bone lesions associated with multiple myeloma, and had received radiation to bone between 1 July 2004 and 1 July 2009. HRU data were extracted from hospital patient charts from 3.5 months before the index SRE (radiation to bone preceded by a SRE-free period of ≥ 6.5 months) until 3 months after the last SRE that the patient experienced during the study period.
Results: In total, 482 patients were included. The number of inpatient stays increased from baseline by a mean of 0.52 (standard deviation [SD] 1.17) stays per radiation to bone event and the duration of stays increased by a mean of 7.8 (SD 14.8) days. Outpatient visits increased by a mean of 4.24 (SD 6.57) visits and procedures by a mean of 8.51 (SD 7.46) procedures.
Conclusion: HRU increased following radiation to bone across all countries studied. Agents that prevent severe pain and delay the need for radiation have the potential to reduce the burden imposed on healthcare resources and patients
Pathologic fracture and healthcare resource utilisation: A retrospective study in eight European countries
Background Skeletal-related events (SREs; pathologic fracture [PF], spinal cord compression and radiation or surgery to bone) are common complications of bone metastases or bone lesions and can impose a considerable burden on patients and healthcare systems. In this study, the healthcare resource utilisation (HRU) associated with PFs in patients with bone metastases or lesions secondary to solid tumours or multiple myeloma was estimated in eight European countries. Methods Eligible patients were identified in Austria, the Czech Republic, Finland, Greece, Poland, Portugal, Sweden and Switzerland. HRU data were extracted from hospital charts from 3.5 months before the index PF (defined as a PF preceded by a 6.5-month period without a SRE) until 3 months after the last SRE during the study period. Changes from baseline in the number and duration of inpatient stays, number of outpatient visits and number of procedures provided were recorded. Results Overall, 118 patients with PFs of long bones (those longer than they are wide, e.g. the femur) and 241 patients with PFs of other bones were included. Overall, HRU was greater in patients with long bone PFs than in those with PFs of other bones. A higher proportion of patients with long bone PFs had multiple SREs (79.7%), and more of their SREs were considered to be linked (73.4%) compared with patients with PFs of other bones (51.0% and 47.2%, respectively). Conclusion The increased number and duration of inpatient stays for PFs of long bones compared with those for PFs of other bones may be due in part to the requirement for complicated and lengthy rehabilitation in patients with long bone PFs. Implementing strategies to delay or reduce the number of PFs experienced by patients with bone metastases or lesions may therefore reduce the associated HRU and patient burden.SCOPUS: ar.jinfo:eu-repo/semantics/publishe
A retrospective study in eight European countries
Background Skeletal-related events (SREs; pathologic fracture [PF], spinal cord compression and radiation or surgery to bone) are common complications of bone metastases or bone lesions and can impose a considerable burden on patients and healthcare systems. In this study, the healthcare resource utilisation (HRU) associated with PFs in patients with bone metastases or lesions secondary to solid tumours or multiple myeloma was estimated in eight European countries. Methods Eligible patients were identified in Austria, the Czech Republic, Finland, Greece, Poland, Portugal, Sweden and Switzerland. HRU data were extracted from hospital charts from 3.5 months before the index PF (defined as a PF preceded by a 6.5-month period without a SRE) until 3 months after the last SRE during the study period. Changes from baseline in the number and duration of inpatient stays, number of outpatient visits and number of procedures provided were recorded. Results Overall, 118 patients with PFs of long bones (those longer than they are wide, e.g. the femur) and 241 patients with PFs of other bones were included. Overall, HRU was greater in patients with long bone PFs than in those with PFs of other bones. A higher proportion of patients with long bone PFs had multiple SREs (79.7%), and more of their SREs were considered to be linked (73.4%) compared with patients with PFs of other bones (51.0% and 47.2%, respectively). Conclusion The increased number and duration of inpatient stays for PFs of long bones compared with those for PFs of other bones may be due in part to the requirement for complicated and lengthy rehabilitation in patients with long bone PFs. Implementing strategies to delay or reduce the number of PFs experienced by patients with bone metastases or lesions may therefore reduce the associated HRU and patient burden.publishersversionpublishe
Healthcare-resource utilization associated with radiation to bone across eight European countries: Results from a retrospective study
Background: Bone metastases and lytic lesions due to multiple myeloma
are common in advanced cancer and can lead to debilitating complications
(skeletal-related events [SREs]), including requirement for radiation
to bone. Despite the high frequency of radiation to bone in patients
with metastatic bone disease, our knowledge of associated healthcare
resource utilization (HRU) is limited.
Methods: This retrospective study estimated HRU following radiation to
bone in Austria, the Czech Republic, Finland, Greece, Poland, Portugal,
Sweden and Switzerland. Eligible patients were >= 20 years old, had bone
metastases secondary to breast, lung or prostate cancer, or bone lesions
associated with multiple myeloma, and had received radiation to bone
between 1 July 2004 and 1 July 2009. HRU data were extracted from
hospital patient charts from 3.5 months before the index SRE (radiation
to bone preceded by a SRE-free period of >= 6.5 months) until 3 months
after the last SRE that the patient experienced during the study period.
Results: In total, 482 patients were included. The number of inpatient
stays increased from baseline by a mean of 0.52 (standard deviation
[SD] 1.17) stays per radiation to bone event and the duration of stays
increased by a mean of 7.8 (SD 14.8) days. Outpatient visits increased
by a mean of 4.24 (SD 6.57) visits and procedures by a mean of 8.51 (SD
7.46) procedures.
Conclusion: HRU increased following radiation to bone across all
countries studied. Agents that prevent severe pain and delay the need
for radiation have the potential to reduce the burden imposed on
healthcare resources and patients
Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry
Abstract Background It is well known that patient characteristics and survival outcomes in randomized trials may not necessarily be similar to those in real-life clinical practice. The aim of the present study was to analyse second line treatment strategies in the real-world practice and to estimate the outcomes of patients treated with second-line targeted therapy for metastatic renal cell carcinoma (mRCC). Methods This is a retrospective, registry-based study using data from the national registry of targeted therapies for mRCC. The RENIS registry contains data on 3049 patients who started the therapy with at least one targeted agent before 31 December, 2014. Of these patients, 1029 had a record of at least two different targeted therapies and sufficient data for analysis. Survival analysis was carried out using the Kaplan-Meier method. Statistical significance of differences in survival between subgroups was assessed using the log-rank test. Results The median overall survival from the start of second-line treatment was 17.0 months (95% confidence interval [CI] 14.5–19.5 months), 17.1 months (95% CI 14.5–19.8), and 15.4 months (95% CI 11.0–19.7) for second-line everolimus, sorafenib, and sunitinib, respectively. Patients receiving second-line everolimus were older at the start of second-line treatment, more likely to have metachronous disease, and less likely to be previously treated with cytokines or to continue to third-line treatment than patients treated with second-line sunitinib or sorafenib. Progression-free survival (PFS) correlated with PFS on first-line treatment only for everolimus. Conclusions In this retrospective study, no significant differences in survival were observed between the cohorts treated with different second-line agents including everolimus, sorafenib, and sunitinib
Pathologic fracture and healthcare resource utilisation: A retrospective study in eight European countries
Background: Skeletal-related events (SREs; pathologic fracture [PF],
spinal cord compression and radiation or surgery to bone) are common
complications of bone metastases or bone lesions and can impose a
considerable burden on patients and healthcare systems. In this study,
the healthcare resource utilisation (HRU) associated with PFs in
patients with bone metastases or lesions secondary to solid tumours or
multiple myeloma was estimated in eight European countries.
Methods: Eligible patients were identified in Austria, the Czech
Republic, Finland, Greece, Poland, Portugal, Sweden and Switzerland. HRU
data were extracted from hospital charts from 3.5 months before the
index PF (defined as a PF preceded by a 6.5-month period without a SRE)
until 3 months after the last SRE during the study period. Changes from
baseline in the number and duration of inpatient stays, number of
outpatient visits and number of procedures provided were recorded.
Results: Overall, 118 patients with PFs of long bones (those longer than
they are wide, e.g. the femur) and 241 patients with PFs of other bones
were included. Overall, HRU was greater in patients with long bone PFs
than in those with PFs of other bones. A higher proportion of patients
with long bone PFs had multiple SREs (79.7%), and more of their SREs
were considered to be linked (73.4%) compared with patients with PFs of
other bones (51.0% and 47.2%, respectively).
Conclusion: The increased number and duration of inpatient stays for PFs
of long bones compared with those for PFs of other bones may be due in
part to the requirement for complicated and lengthy rehabilitation in
patients with long bone PFs. Implementing strategies to delay or reduce
the number of PFs experienced by patients with bone metastases or
lesions may therefore reduce the associated HRU and patient burden